ISTA Pharmaceuticals Inc. (Nasdaq:ISTA) announced it will release third quarter 2011 financial results after the market closes on November 1, 2011. In conjunction, the Company will host a conference call at 4:30 p.m.
ISTA Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets remedies for diseases and conditions of the eye in the United States.
Theratechnologies Inc. (Nasdaq:THER) announced its financial results for the three-month and nine-month periods ended August 31, 2011. Consolidated revenues rose sharply to $3.5 million for the third quarter of 2011 and $10.5 million for nine-month period. R&D expenses, which include costs related to the launch of the muscle. wasting in COPD clinical program, remain stable at $2.9 million for the quarter Liquidities of $40 million available at quarter end.
Theratechnologies Inc., a specialty pharmaceutical company, engages in the discovery and development of therapeutic peptide products with a focus on growth-hormone releasing factor (GRF) peptides.
MAJESTIC GOLD CORP (MJGCF.PK)
The most important industrial use of gold is in the manufacture of electronics. Solid state electronic devices use very low voltages and currents which are easily interrupted by corrosion or tarnish at the contact points. Gold is the highly efficient conductor that can carry these tiny currents and remain free of corrosion. Electronic components made with gold are highly reliable. Gold is used in connectors, switch and relay contacts, soldered joints, connecting wires and connection strips.
MAJESTIC GOLD CORP (MJGCF.PK) engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.
MAJESTIC GOLD CORP (MJGCF.PK) has arranged a $10,000,000 loan to advance its Song Jiagou project in China. Nine million dollars ($9,000,000) from the proceeds from the loan will be used by the Company to in connection with its Song Jiagou project and the balance of one million dollars ($1,000,000) for general working capital purposes.
The loan will have a one year term and loan principal will be convertible at the option of the lender in whole or in part into common shares (”Shares”) of the Company until twelve months from the date of the loan advance at the price of $0.205 per Share. The loan will bear interest at the rate of 7.5% per annum, payable on maturity, and accrued and unpaid interest will be convertible at the option of the lender in whole or in part into shares of the Company until twelve months from the date of the loan advance at Market Price at the time of conversion.
The lender is at arm’s length from the Company and will not become an insider as a result of any conversion of principal and interest. All shares issued on any conversion of loan principal or interest will be subject to a four month hold period from the date of advance of loan proceeds. The loan is subject to acceptance by the TSX Venture Exchange.
As additional consideration for the loan, the Company has agreed to forward at least $9 million to Majestic Yantai Gold Ltd., a British Virgin Islands company owned 94% by the Company to be used to further advance its Song Jiagou project. The Borrower has also agreed to a 90 day period for reciprocal due diligence reviews and discussions for the possible further involvement of the Lender in the Song Jiagou project.
In the event that no further agreement is reached between the Lender and the Company during the 90 day period, then the loan and a minimum of seven (7) months interest will automatically convert to shares in the Company at a price of $0.205 per share and the interest at Market Price respectively. In addition the Company is pleased to announce that it has arranged a non-brokered private placement of up to 15,000,000 shares to be issued at the price of $0.20 per share for gross proceeds of $3,000,000.
For more information about MAJESTIC GOLD CORP. visit its website: http://www.majesticgold.net
Accelrys Inc. (Nasdaq:ACCL) announced a strategic collaboration with The Edge Software Consultancy Ltd. to offer new assay, study management and analysis software solutions that improve R&D efficiency and productivity for biopharmaceutical organizations engaged in early-stage screening through ADME, DMPK, pharmacology and in vivo experimentation.
Accelrys, Inc. develops and commercializes scientific informatics software products and services for industries and organizations that rely on scientific innovation to differentiate themselves in the marketplace.
No comments:
Post a Comment